Regeneron purchase of the 23andMe assets, including its consumer genetic biobank, out of bankruptcy
$256 million
USD per company acquisition (one deal), US
“Regeneron Pharmaceuticals purchased the collapsed genetic testing firm for $256 million”
Quartz, 23andMe just got bought out of bankruptcy (May 2025), 2025-05
- Kind of source
- Named press report
- Read on
- 2026-11-06
- Daily check
- Source re-read on 2026-11-06 needs a browser (PDF or protected page)
- What to know
- This is an acquisition of a whole company (brand, lab, biobank) in a distressed sale, not a data licence, and the telehealth unit was excluded. It is a low anchor for the value of a consumer genetic biobank.
- About
- Consumer DNA test
Used in
Kept as evidence; no figure on the platform is computed from it yet.